185 related articles for article (PubMed ID: 30706390)
1. Practical Considerations for the Use of DREADD and Other Chemogenetic Receptors to Regulate Neuronal Activity in the Mammalian Brain.
Aldrin-Kirk P; Björklund T
Methods Mol Biol; 2019; 1937():59-87. PubMed ID: 30706390
[TBL] [Abstract][Full Text] [Related]
2. The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats.
Campbell EJ; Marchant NJ
Br J Pharmacol; 2018 Apr; 175(7):994-1003. PubMed ID: 29338070
[TBL] [Abstract][Full Text] [Related]
3. Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.
Burnett CJ; Krashes MJ
J Neurosci; 2016 Sep; 36(36):9268-82. PubMed ID: 27605603
[TBL] [Abstract][Full Text] [Related]
4. Gi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory Neurons.
Saloman JL; Scheff NN; Snyder LM; Ross SE; Davis BM; Gold MS
J Neurosci; 2016 Oct; 36(42):10769-10781. PubMed ID: 27798132
[TBL] [Abstract][Full Text] [Related]
5. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
[TBL] [Abstract][Full Text] [Related]
6. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
Urban DJ; Roth BL
Annu Rev Pharmacol Toxicol; 2015; 55():399-417. PubMed ID: 25292433
[TBL] [Abstract][Full Text] [Related]
7. DREADD: a chemogenetic GPCR signaling platform.
Zhu H; Roth BL
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25522378
[TBL] [Abstract][Full Text] [Related]
8. Multimodal Imaging for Validation and Optimization of Ion Channel-Based Chemogenetics in Nonhuman Primates.
Hori Y; Nagai Y; Hori Y; Oyama K; Mimura K; Hirabayashi T; Inoue KI; Fujinaga M; Zhang MR; Takada M; Higuchi M; Minamimoto T
J Neurosci; 2023 Sep; 43(39):6619-6627. PubMed ID: 37620158
[TBL] [Abstract][Full Text] [Related]
9. Chemogenetics drives paradigm change in the investigation of behavioral circuits and neural mechanisms underlying drug action.
Ozawa A; Arakawa H
Behav Brain Res; 2021 May; 406():113234. PubMed ID: 33741409
[TBL] [Abstract][Full Text] [Related]
10. Chemogenetic tools to interrogate brain functions.
Sternson SM; Roth BL
Annu Rev Neurosci; 2014; 37():387-407. PubMed ID: 25002280
[TBL] [Abstract][Full Text] [Related]
11. Viral Vector Delivery of DREADDs for CNS Therapy.
Pickering CA; Mazarakis ND
Curr Gene Ther; 2021; 21(3):191-206. PubMed ID: 33573551
[TBL] [Abstract][Full Text] [Related]
12. How structure informs and transforms chemogenetics.
Roth BL
Curr Opin Struct Biol; 2019 Aug; 57():9-16. PubMed ID: 30818201
[TBL] [Abstract][Full Text] [Related]
13. Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice.
Zhu H; Aryal DK; Olsen RH; Urban DJ; Swearingen A; Forbes S; Roth BL; Hochgeschwender U
Genesis; 2016 Aug; 54(8):439-46. PubMed ID: 27194399
[TBL] [Abstract][Full Text] [Related]
14. Chemogenetic approaches to identify metabolically important GPCR signaling pathways: Therapeutic implications.
Meister J; Wang L; Pydi SP; Wess J
J Neurochem; 2021 Aug; 158(3):603-620. PubMed ID: 33540469
[TBL] [Abstract][Full Text] [Related]
15. Optogenetic and chemogenetic therapies for epilepsy.
Walker MC; Kullmann DM
Neuropharmacology; 2020 May; 168():107751. PubMed ID: 31494141
[TBL] [Abstract][Full Text] [Related]
16. Multimodal Imaging for DREADD-Expressing Neurons in Living Brain and Their Application to Implantation of iPSC-Derived Neural Progenitors.
Ji B; Kaneko H; Minamimoto T; Inoue H; Takeuchi H; Kumata K; Zhang MR; Aoki I; Seki C; Ono M; Tokunaga M; Tsukamoto S; Tanabe K; Shin RM; Minamihisamatsu T; Kito S; Richmond BJ; Suhara T; Higuchi M
J Neurosci; 2016 Nov; 36(45):11544-11558. PubMed ID: 27911758
[TBL] [Abstract][Full Text] [Related]
17. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
[TBL] [Abstract][Full Text] [Related]
18. Chemogenetics a robust approach to pharmacology and gene therapy.
Keifer O; Kambara K; Lau A; Makinson S; Bertrand D
Biochem Pharmacol; 2020 May; 175():113889. PubMed ID: 32119836
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity.
Zhan J; Komal R; Keenan WT; Hattar S; Fernandez DC
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31498301
[TBL] [Abstract][Full Text] [Related]
20. Allosteric modulation of a chemogenetically modified G protein-coupled receptor.
Abdul-Ridha A; Lane JR; Sexton PM; Canals M; Christopoulos A
Mol Pharmacol; 2013 Feb; 83(2):521-30. PubMed ID: 23197649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
